Kelly Toms is new Director of Business Development at Meridien Research

Kelly joined Meridien Research in 2014 and has worked in operations, regulatory, accounting, marketing and business development. She was initially hired as a Regulatory and Clinical Research Associate. Since then, Kelly successfully started and completed a company-wide records archival, assisted with site regulatory needs, performed data entry for more than 100 trials and was involved in business-to-business (B2B) and business-to-consumer (B2C) marketing. In addition, she managed Meridien Research’s social media platforms, while also overseeing the institutional submissions and approvals for all advertising materials.

Kelly’s most recent role in Business Development has enhanced her knowledge of the federal regulations for clinical trials and pharmaceutical drug development, while providing her with extensive practice in business-to-business sales.

“As our capabilities, therapeutic and indication coverage and network grows, we need a second Business Development Director to manage the needs of all clinical drug development opportunities,” Meridien Research CEO Tony Busa explained. “Kelly’s promotion ensures our coverage is more exact and contact frequency by phone and email will be greater.”

Kelly graduated with a Bachelor of Arts in English from the University of South Florida in 2014. In her spare time, you can find Kelly visiting animals at area wildlife sanctuaries, exploring local nature preserves or enjoying the beach with her beloved dogs.

For more information, contact Kelly Toms at or 727-347-8839.

About Meridien Research

Meridien Research has been conducting clinical research trials and studies since 2000 in central Florida.  All studies are administered by board certified doctors and highly-trained medical personnel in St. Petersburg, Tampa, Bradenton, Brooksville, Lakeland and Maitland.